FDA develops new framework for psychedelic therapies

The U.S. Food and Drug Administration (FDA) is developing a new framework to accelerate patient access to psychedelic medicines in response to the ongoing national mental health crisis. FDA officials noted that while current medications are insufficient for some patients, psychedelic compounds like psilocybin and DMT may offer potential avenues for better treatment.

To facilitate this, the agency recently held a public hearing at its White Oak Campus in Maryland, attended by approximately 300 people in person and 1,000 via livestream. During the hearing, participants provided input on patient safety, provider training, and data standardization.

A recurring theme among commenters was the need to treat psychedelics as part of a broader therapeutic package rather than isolated drugs. Experts emphasized the importance of psychedelic-assisted therapy, highlighting the necessity of clinical preparation and integration, as well as the role of the therapeutic relationship in successful outcomes.